Michigan physicians may now authorize cannabis for the treatment of post traumatic stress.
Members of the Medical Marihuana Review Panel voted 6 to 2 to expand the state’s list of qualifying conditions to include PTSD. The Director of the Michigan Department of Licensing and Regulatory Affairs has signed off on the recommendation.
This is the first time that regulators have expanded the state’s list of qualifying conditions since voters initially legalized the physician authorized use of cannabis in 2008.
Six other states — Connecticut, Delaware, Maine, New Mexico, Nevada, and Oregon — explicitly allow for the use of cannabis to treat symptoms of post-traumatic stress. Nevada regulators expanded their law to include PTSD earlier this year. Oregon and Maine lawmakers amended their medical cannabis laws last year to include post-traumatic stress.
California physicians may recommend medical cannabis at their discretion.
Clinical trial data published in the May issue of the journal Molecular Psychiatry theorized that cannabinoid-based therapies would likely comprise the “next generation of evidence-based treatments for PTSD (post-traumatic stress disorder).”
Post-traumatic stress syndrome is an anxiety disorder that is estimated to impact some eight million Americans annually. To date, there are no pharmaceutical treatments specifically designed or approved to target symptoms of PTSD.
Last week, federal officials at the Public Health Service approved the use of cannabis in a privately funded pilot trial at the University of Arizona College of Medicine to assess its potential risks and benefits in war veterans suffering from PTSD, including the plant’s potential impact on subjects’ anxiety, suicidality, and depression. Although the study was initially approved by the FDA in 2011, neither PHS nor the US National Institute on Drug Abuse (NIDA) signed off on the protocol until this month. Both agencies, as well as the US DEA, must approve any clinical trial involving cannabis.
A rise in the self-reported consumption of cannabis during the years 2006 to 2010 corresponds with a significant decline in Americans’ use of cocaine and methamphetamine during this same time period, according to a new RAND study commissioned by the White House Office of National Drug Control Policy (ONDCP).
Researchers estimate that Americans increased their consumption of cannabis by approximately 30 percent during the years 2006 to 2010. During this same time, authors estimated that the public’s use of cocaine and methamphetamine declined, with Americans’ use of cocaine falling by half.
Americans’ consumption of heroin remained largely stable throughout the decade, the study reported. According to statistics compiled by the US Substance Abuse And Mental Health Services Administration, an estimated 4.5 million Americans have tried heroin in their lifetimes. By comparison, an estimated 12 million Americans have tried methamphetamine, 37.5 million have tried cocaine, and 111 million have consumed cannabis.
Authors estimated that Americans spent approximately one trillion dollars on the purchase of cocaine, heroin, marijuana and methamphetamine between 2000 and 2010.
Commenting on the report, NORML Deputy Director Paul Armentano said, “These figures belie that notion that marijuana exposure is an alleged ‘gateway’ to the use of other illicit substances and instead suggest that for some people, cannabis may be a substitute for other so-called ‘hard drugs’ or even an exit drug.”
Survey data published in 2013 in the journal Addiction Research & Theory reported that among a cohort of medical marijuana consumers, 75 percent of subjects acknowledged that they used cannabis it as a substitute for prescription drugs, alcohol, or some other illicit substance.
A 2010 study published in the Harm Reduction Journal reported that cannabis-using adults enrolled in substance abuse treatment programs fared equally or better than nonusers in various outcome categories, including treatment completion.
Full text of the study, “”What America’s Users Spend on Illegal Drugs, 2000-2010,” is available online from the Office of National Drug Control Policy here.
Inhaling whole-plant cannabis provides symptomatic relief in patients with Parkinson’s disease (PD), according to observational trial data published in the March/April edition of the journal Clinical Neuropharmacology. Parkinson’s is a progressive disorder of the central nervous system that results in tremor, slowed movement, and muscle rigidity.
Investigators at Tel Aviv University, Department of Neurology evaluated Parkinson’s disease symptoms in 22 patients at baseline and 30-minutes after inhaling cannabis.
Researchers reported that inhaled cannabis was associated with “significant improvement after treatment in tremor, rigidity, and bradykinsea (slowness of movement). There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed.”
They concluded: “[T]his observational study is the first to report an amelioration of both motor and non–motor symptoms in patients with PD treated with cannabis. The study opens new venues for treatment strategies in PD especially in patients refractory to current medications.”
Israel has formally allowed for the licensed production and distribution of the substance for therapeutic purposes since 2011.
An abstract of the study, “Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study,” is online here.
In recent weeks, lawmakers in several states have moved forward with legislative proposals to permit specific strains and/or extracts of cannabis possessing high quantities of the cannabinoid cannabidiol (CBD), but otherwise maintaining criminal prohibitions on the whole plant.
But is this new direction in the best interest of patients? As I wrote in a recent column for Alternet.org (republished with permission by Cannabis Now under the title “Patients Ought To Be Skeptical Of Proposed CBD-Only Legislation — Here’s Why”), I believe the answer is ‘no.’
Ultimately, patients should not be unnecessarily forced to decide between either accessing the whole plant or its isolated components. They should have safe, legal access to both, and politicians, even well-intentioned ones, should not restrict patients’ right to choose the most suitable option.
Below are excerpts from my commentary. You can read the entire text here.
Patients Ought To Be Skeptical Of Proposed CBD-Only Legislation — Here’s Why
via Cannabis Now
[excerpt] If the plant ain’t broke, why fix it?
For longtime marijuana law reformers, the ongoing political conversation surrounding CBD is instructive. It makes it clear that many politicians’ public opposition to the idea of patients using marijuana therapeutically isn’t because of supposed unanswered questions surrounding the plant’s safety or efficacy. Rather, it is because lawmakers oppose the idea of some people getting high from a naturally growing herb. (The fact that patients can get equally high or even higher from FDA-approved synthetic THC has, for whatever reason, never been an expressed concern of either lawmakers or prohibitionists.) After all, the very same politicians who argue that marijuana isn’t medicine because it hasn’t been approved by the FDA or who allege that the substance hasn’t yet been subjected to sufficient scientific scrutiny utter no such public objections to the idea of legalizing patient access to CBD – a schedule I compound that hasn’t been reviewed, much less approved by the FDA, and that has been clinically studied far less than cannabis.
Perhaps most ironically is that were it not for the advent of legalized whole plant marijuana, a policy change publicly opposed by many present day CBD-only political advocates, lawmakers (and anti-pot groups like SAM) today wouldn’t be aware of CBD, much less advocating for it. The reality is that it was the stakeholders in medical marijuana states, and those who provide for them, who have done the most to explore and promote cannabidiol as a legitimate therapeutic agent. And they were able to do so because they, unlike most federally licensed medical researchers, had access to the whole plant.
We’ve been down this road before. Not long ago, lawmakers and anti-marijuana zealots were dismissing patients’ desire to access the marijuana plant because they alleged that the THC-pill Marinol could adequately meet patients’ needs. Patients and their advocates were skeptical of lawmakers’ claims then, and properly so. Now many of these same politicians are once again dismissing patients’ calls for whole plant medicine by claiming that products and strains containing CBD alone only will suffice. Patients and their advocates ought to be equally skeptical once again.
CNN Chief Medical Correspondent Dr. Sanjay Gupta is “doubling down” in his advocacy for patients to have legal access to cannabis as a therapeutic agent.
In a commentary featured on the CNN website today, Gupta writes: “I am more convinced than ever that it is irresponsible to not provide the best care we can, care that often may involve marijuana. I am not backing down on medical marijuana; I am doubling down.”
Last August, Gupta authored a commentary apologizing for his past opposition to medical cannabis, stating, “We have been terribly and systematically misled for nearly 70 years in the United States (in regards to cannabis), and I apologize for my own role in that.”
In today’s editorial, Gupta acknowledges, “Marijuana is classified as a Schedule I substance, defined as (one of) the most dangerous drugs with no currently accepted medical use. Neither of those statements has ever been factual.”
He criticizes President Obama for acknowledging that cannabis poses less harm than alcohol while failing “to remove marijuana from the list of the most tightly controlled substances in the country.” Dr. Gupta also questions how the US government can possess a patent on the therapeutic application of cannabinoids yet still deny that the compounds possess medical utility.
Ultimately, cannabis prohibition is a “Draconian system where politics override science,” Gupta concludes.
Gupta’s forthcoming documentary on the plant, entitled “Weed 2: Cannabis Madness: Dr. Sanjay Gupta Reports,” at 10 p.m. ET on Tuesday, March 11.